<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732901</url>
  </required_header>
  <id_info>
    <org_study_id>HM15289</org_study_id>
    <secondary_id>P20DA024157</secondary_id>
    <secondary_id>DA 024157</secondary_id>
    <nct_id>NCT00732901</nct_id>
  </id_info>
  <brief_title>Clinical Neurobiology of Serotonin and Addiction</brief_title>
  <official_title>Project 1: Clinical Neurobiology of Serotonin and Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the relationship between 5-HT2R function, impulsivity
      and cue reactivity in cocaine dependent subjects and healthy controls and examine specific
      effects of escitalopram and mirtazapine on impulsivity and cue reactivity in human cocaine
      users.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: We will test the hypothesis that cocaine-dependent subjects will exhibit
      greater impulsivity than controls as determined by a battery of impulsivity measures and that
      impulsivity will be associated with specific profiles of 5-HT2AR and/or 5-HT2CR expression in
      platelets. We predict that treatment of cocaine-dependent subjects with escitalopram and/or
      mirtazapine will reduce impulsivity and cocaine-positive urines, in concert with a normalized
      balance of platelet 5-HT2AR and/or 5-HT2CR expression.

      Specific Aim 2: We will test the hypothesis that cocaine-dependent subjects will exhibit
      greater cue reactivity than controls as determined by a modified Stroop task, and that cue
      reactivity will be associated with specific profiles of 5-HT2AR and/or 5-HT2CR expression in
      platelets. We predict that treatment of cocaine-dependent subjects with escitalopram and/or
      mirtazapine will reduce cue reactivity and cocaine-positive urines, in concert with a
      normalized balance of platelet 5-HT2AR and/or 5-HT2CR expression.

      Specific Aim 3: We will test the hypothesis that specific polymorphisms in the 5-HT2AR and/or
      5-HT2CR will predict baseline impulsivity and/or cue reactivity as well as treatment response
      to serotonergic medications in cocaine-dependent subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate Memory Task</measure>
    <time_frame>after acute dose and after chronic administration</time_frame>
    <description>The IMT was used to measure impulsivity. The IMT is a continuous performance test. Subjects were instructed to respond on the computer's left mouse button when a five-digit number the target stimulus appeared that was exactly like the preceding stimulus. A catch stimulus was a number that differed only slightly from the preceding number. Only one of the five digits was changed its position and value was determined randomly. Responses errors made to catch stimuli were considered commission errors or 'false alarms'. Immediate Memory Task Commission Errors to catch stimuli were the primary measure of impulsivity in this study. Scale is percentage of overall responses to a catch stimulus that were commission errors, ranging from 0 to 100. Zero would equate to no impulsivity and 100 would equate to 100% impulsive responses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attentional Bias as Measured by the Cocaine Stroop Task.</measure>
    <time_frame>5 weeks of treatment</time_frame>
    <description>Attentional bias is the difference in reaction time to cocaine related words and neutral words. A slower reaction time indicates greater attentional bias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cocaine Positive Urines</measure>
    <time_frame>5 weeks of treatment</time_frame>
    <description>Number of urine drug screens positive for cocaine metabolite benzoylecgonine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>A (escitalopram)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28</description>
    <arm_group_label>A (escitalopram)</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily days 1-28</description>
    <arm_group_label>B (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-Drug Abusing Control Subjects: Male and female subjects age 18 to 55 who do not
             meet current or past DSM-IV criteria for any Axis I disorder including substance abuse
             or dependence.

          -  Cocaine Dependent Subjects: Male and female subjects age 18 to 55 who meet current
             DSM-IV criteria for cocaine dependence.

          -  Female subjects: a negative pregnancy test.

        Exclusion Criteria:

          -  Non-Drug Abusing Control Subjects:

               1. Current or past DSM-IV Axis I disorder

               2. Any serious non-psychiatric medical illness requiring ongoing medical treatment
                  or which could affect the central nervous system.

               3. Positive HIV test.

               4. For female subjects: a positive pregnancy test or breast feeding.

               5. Concomitant use of prescription medications that could affect the central nervous
                  system.

               6. Active suicidal ideation.

               7. Hamilton Depression or Anxiety Scale score greater than 15

          -  Cocaine Dependent Subjects:

               1. Current DSM-IV Axis I disorder other than substance abuse/dependence

               2. Current diagnosis of other substance dependence besides cocaine.

               3. Any serious non-psychiatric medical illness requiring ongoing medical treatment
                  or which could affect the central nervous system.

               4. Positive HIV test.

               5. For female subjects: a positive pregnancy test or breast feeding.

               6. Concomitant use of prescription medications that could affect the central nervous
                  system.

               7. Active suicidal ideation.

               8. Subjects within 14 days of discontinuing a monoamine oxidase inhibitor.

               9. Subjects with cardiac arrythmias.

              10. Subjects with known hypersensitivity to escitalopram or citalopram, or
                  mirtazapine

              11. Hamilton Depression or Anxiety Scale score greater than 15.

              12. Current alcohol abuse or dependence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick G Moeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center-Houston; Substance Abuse Research Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Liu S, Lane SD, Schmitz JM, Waters AJ, Cunningham KA, Moeller FG. Relationship between attentional bias to cocaine-related stimuli and impulsivity in cocaine-dependent subjects. Am J Drug Alcohol Abuse. 2011 Mar;37(2):117-22. doi: 10.3109/00952990.2010.543204. Epub 2011 Jan 5.</citation>
    <PMID>21204739</PMID>
  </results_reference>
  <results_reference>
    <citation>Anastasio NC, Liu S, Maili L, Swinford SE, Lane SD, Fox RG, Hamon SC, Nielsen DA, Cunningham KA, Moeller FG. Variation within the serotonin (5-HT) 5-HT₂C receptor system aligns with vulnerability to cocaine cue reactivity. Transl Psychiatry. 2014 Mar 11;4:e369. doi: 10.1038/tp.2013.131.</citation>
    <PMID>24618688</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu S, Lane SD, Schmitz JM, Cunningham KA, John VP, Moeller FG. Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects. J Psychopharmacol. 2013 Sep;27(9):801-7. doi: 10.1177/0269881113492898. Epub 2013 Jun 12.</citation>
    <PMID>23761390</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <results_first_submitted>July 20, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2017</results_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>substance abuse</keyword>
  <keyword>cocaine</keyword>
  <keyword>impulsivity</keyword>
  <keyword>serotonin</keyword>
  <keyword>Remeron</keyword>
  <keyword>Mirtzapine</keyword>
  <keyword>Lexapro</keyword>
  <keyword>Escatilopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The enrollment number was the number of participants who signed the informed consent. The Participants who Started in the Participant flow module were number of participants who completed the screening and met inclusion criteria to start medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A (Escitalopram)</title>
          <description>Escitalopram
Escitalopram: once daily 10 mg on days 1–3, 20 mg on days 4–24 and 10 mg on days 25–28</description>
        </group>
        <group group_id="P2">
          <title>B (Placebo)</title>
          <description>Placebo
Placebo: once daily for days 1-28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A (Escitalopram)</title>
          <description>Escitalopram: once daily 10 mg on days 1–3, 20 mg on days 4–24 and 10 mg on days 25–28</description>
        </group>
        <group group_id="B2">
          <title>B (Placebo)</title>
          <description>Placebo once daily for days 1-28</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="7.88"/>
                    <measurement group_id="B2" value="41.75" spread="6.65"/>
                    <measurement group_id="B3" value="40.01" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immediate Memory Task</title>
        <description>The IMT was used to measure impulsivity. The IMT is a continuous performance test. Subjects were instructed to respond on the computer’s left mouse button when a five-digit number the target stimulus appeared that was exactly like the preceding stimulus. A catch stimulus was a number that differed only slightly from the preceding number. Only one of the five digits was changed its position and value was determined randomly. Responses errors made to catch stimuli were considered commission errors or ‘false alarms’. Immediate Memory Task Commission Errors to catch stimuli were the primary measure of impulsivity in this study. Scale is percentage of overall responses to a catch stimulus that were commission errors, ranging from 0 to 100. Zero would equate to no impulsivity and 100 would equate to 100% impulsive responses.</description>
        <time_frame>after acute dose and after chronic administration</time_frame>
        <population>Numerical data values are not accessible because PI transferred institutions. See references.</population>
        <group_list>
          <group group_id="O1">
            <title>A (Escitalopram)</title>
            <description>Escitalopram
Escitalopram: 10 mg daily for days 1-3, 20mg daily for days 4-24, and 10mg daily for days 25-28</description>
          </group>
          <group group_id="O2">
            <title>B (Placebo)</title>
            <description>Placebo
Placebo: daily for days 1-28</description>
          </group>
        </group_list>
        <measure>
          <title>Immediate Memory Task</title>
          <description>The IMT was used to measure impulsivity. The IMT is a continuous performance test. Subjects were instructed to respond on the computer’s left mouse button when a five-digit number the target stimulus appeared that was exactly like the preceding stimulus. A catch stimulus was a number that differed only slightly from the preceding number. Only one of the five digits was changed its position and value was determined randomly. Responses errors made to catch stimuli were considered commission errors or ‘false alarms’. Immediate Memory Task Commission Errors to catch stimuli were the primary measure of impulsivity in this study. Scale is percentage of overall responses to a catch stimulus that were commission errors, ranging from 0 to 100. Zero would equate to no impulsivity and 100 would equate to 100% impulsive responses.</description>
          <population>Numerical data values are not accessible because PI transferred institutions. See references.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Attentional Bias as Measured by the Cocaine Stroop Task.</title>
        <description>Attentional bias is the difference in reaction time to cocaine related words and neutral words. A slower reaction time indicates greater attentional bias.</description>
        <time_frame>5 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A (Escitalopram)</title>
            <description>Escitalopram
Escitalopram: 10 mg daily for days 1-3, 20mg daily for days 4-24, and 10mg daily for days 25-28</description>
          </group>
          <group group_id="O2">
            <title>B (Placebo)</title>
            <description>Placebo
Placebo: daily for days 1-28</description>
          </group>
        </group_list>
        <measure>
          <title>Attentional Bias as Measured by the Cocaine Stroop Task.</title>
          <description>Attentional bias is the difference in reaction time to cocaine related words and neutral words. A slower reaction time indicates greater attentional bias.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" spread="107.8"/>
                    <measurement group_id="O2" value="45.9" spread="109.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="21.6"/>
                    <measurement group_id="O2" value="37.4" spread="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="58.7"/>
                    <measurement group_id="O2" value="35.4" spread="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="68.6"/>
                    <measurement group_id="O2" value="15.4" spread="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="33.0"/>
                    <measurement group_id="O2" value="-11.3" spread="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" spread="82.5"/>
                    <measurement group_id="O2" value="4.4" spread="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Positive Urines</title>
        <description>Number of urine drug screens positive for cocaine metabolite benzoylecgonine.</description>
        <time_frame>5 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A (Escitalopram)</title>
            <description>Escitalopram
Escitalopram: 10 mg daily for days 1-3, 20mg daily for days 4-24, and 10mg daily for days 25-28</description>
          </group>
          <group group_id="O2">
            <title>B (Placebo)</title>
            <description>Placebo
Placebo: daily for days 1-28</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Positive Urines</title>
          <description>Number of urine drug screens positive for cocaine metabolite benzoylecgonine.</description>
          <units>Positive urine drug screens</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>A (Escitalopram)</title>
          <description>Escitalopram
Escitalopram: once daily 10 mg on days 1–3, 20 mg on days 4–24 and 10 mg on days 25–28</description>
        </group>
        <group group_id="E2">
          <title>B (Placebo)</title>
          <description>Placebo
Placebo: once daily for days 1-28</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>F. Gerard Moeller</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-4134</phone>
      <email>fgmoeller@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

